Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Adenosine cyclophosphate (also known as cyclic AMP or cAMP) is a naturally occurring intracellular second messenger that plays a critical role in mediating cellular responses to various extracellular signals, such as hormones and neurotransmitters. As a therapeutic agent, adenosine cyclophosphate is formulated as an injection and is approved in China for the treatment of cardiovascular and other conditions, including angina pectoris, myocardial infarction, myocarditis, cardiogenic shock, rheumatic heart disease, acute leukemia, chronic bronchitis, hepatitis, and psoriasis. Mechanistically, it acts as an agonist that binds to and activates the regulatory subunits of cAMP-dependent protein kinase (Protein Kinase A or PKA) and exchange proteins activated by cAMP (EPAC1 and EPAC2), thereby regulating downstream phosphorylation cascades, cellular metabolism, and gene expression.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on adenosine cyclophosphate.